Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...